Johnson & Johnson (NYSE:JNJ) Shares Sold by Rice Hall James & Associates LLC

Posted by on Apr 16th, 2023

Rice Hall James & Associates LLC lowered its holdings in Johnson & Johnson (NYSE:JNJ – Get Rating) by 8.1% in the fourth quarter, according to the company in its most recent disclosure with the SEC. The firm owned 10,207 shares of the company’s stock after selling 895 shares during the quarter. Rice Hall James & Associates LLC’s holdings in Johnson & Johnson were worth $1,803,000 as of its most recent filing with the SEC.

A number of other hedge funds and other institutional investors also recently bought and sold shares of the business. Glassy Mountain Advisors Inc. acquired a new position in shares of Johnson & Johnson during the 4th quarter worth $35,000. Retirement Financial Solutions LLC acquired a new position in Johnson & Johnson in the 4th quarter valued at about $40,000. TD Capital Management LLC acquired a new position in Johnson & Johnson in the 3rd quarter valued at about $48,000. Iron Horse Wealth Management LLC raised its stake in Johnson & Johnson by 112.8% in the 4th quarter. Iron Horse Wealth Management LLC now owns 300 shares of the company’s stock valued at $53,000 after purchasing an additional 159 shares during the last quarter. Finally, Cowa LLC acquired a new position in Johnson & Johnson in the 3rd quarter valued at about $58,000. Institutional investors and hedge funds own 67.94% of the company’s stock.

Johnson & Johnson Stock Performance

Shares of JNJ opened at $165.84 on Friday. The business’s 50 day moving average is $157.46 and its two-hundred day moving average is $167.02. Johnson & Johnson has a 52-week low of $150.11 and a 52-week high of $186.69. The firm has a market cap of $431.90 billion, a price-to-earnings ratio of 24.61, a PEG ratio of 2.83 and a beta of 0.53. The company has a quick ratio of 0.77, a current ratio of 0.99 and a debt-to-equity ratio of 0.35.

Johnson & Johnson (NYSE:JNJ – Get Rating) last announced its earnings results on Tuesday, January 24th. The company reported $2.35 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.22 by $0.13. Johnson & Johnson had a return on equity of 35.76% and a net margin of 18.90%. The company had revenue of $23.71 billion for the quarter, compared to analyst estimates of $23.90 billion. During the same period in the prior year, the company posted $2.13 EPS. Johnson & Johnson’s quarterly revenue was down 4.4% on a year-over-year basis. Analysts forecast that Johnson & Johnson will post 10.49 EPS for the current fiscal year.

Analyst Ratings Changes

Several research analysts recently weighed in on JNJ shares. StockNews.com started coverage on shares of Johnson & Johnson in a research note on Thursday, March 16th. They issued a “strong-buy” rating for the company. Cantor Fitzgerald restated an “overweight” rating and issued a $215.00 price target on shares of Johnson & Johnson in a report on Wednesday, February 1st. Atlantic Securities lifted their price target on Johnson & Johnson from $160.00 to $168.00 and gave the company a “neutral” rating in a report on Wednesday, January 25th. SVB Leerink lowered their price target on Johnson & Johnson from $194.00 to $186.00 and set an “outperform” rating for the company in a report on Friday, January 20th. Finally, Guggenheim initiated coverage on Johnson & Johnson in a report on Tuesday, February 28th. They issued a “neutral” rating and a $161.00 price target for the company. Seven investment analysts have rated the stock with a hold rating, six have given a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $173.07.

Insider Activity at Johnson & Johnson

In related news, insider James D. Swanson sold 1,062 shares of the company’s stock in a transaction that occurred on Monday, March 6th. The stock was sold at an average price of $154.66, for a total transaction of $164,248.92. Following the sale, the insider now directly owns 9,215 shares of the company’s stock, valued at approximately $1,425,191.90. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Corporate insiders own 0.20% of the company’s stock.

Johnson & Johnson Profile

(Get Rating)

Johnson & Johnson is a holding company, which engages in the research and development, manufacture and sale of products in the health care field. It operates through the following segments: Consumer Health, Pharmaceutical, and MedTech. The Consumer Health segment includes products focused on personal healthcare used in the Skin Health/Beauty, Over-the-Counter medicines, Baby Care, Oral Care, Women’s Health and Wound Care markets.

Recommended Stories

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.